Results 191 to 200 of about 2,668,255 (357)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Identification of Sjögren's disease-associated T cell receptor motifs through deep sequencing. [PDF]

JCI Insight
Jupudi AA, Joachims ML, Lawrence C, Lopez-Davis C, Khatri B, Rasmussen A, Grundahl K, Scofield RH, James JA, Guthridge JM, Lessard CJ, Thompson LF, Farris AD.   +12 more
europepmc   +1 more source

Investigation of T cell receptor and immunoglobulin repertoire through next generation sequencing data

, 2017
Yaxuan Yu
openalex   +2 more sources

Coordinate gene expression of luteinizing hormone-releasing hormone (LHRH) and the LHRH-receptor after prolactin stimulation in the rat Nb2 T-cell line: implications for a role in immunomodulation and cell cycle gene expression. [PDF]

, 1995
T M Wilson, Li‐Yuan Yu‐Lee, Mark R. Kelley   +2 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

T-cell receptor therapy in ovarian cancer: concepts and challenges. [PDF]

J Ovarian Res
Wang X, Li Z, Zhang M, Yu Y, Tong W.
europepmc   +1 more source

Soluble interleeukin-2 receptors and cutaneous t-cell lymphoma [PDF]

, 1993
Reinhard Dummer, Günter Burg, Frank O. Nestlé, Oliver Kohl, Rolf‐Markus Szeimies, F. Ruëff, Peter Kaudewitz   +6 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

γδ T cell receptor recognition of CD1d in a lipid-independent manner. [PDF]

Nat Commun
Rice MT, Gunasinghe SD, Sok CL, Pan M, Lay CS, Gully BS, Rossjohn J.   +6 more
europepmc   +1 more source

Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents [PDF]

, 2018
Huimin Zou, Ruixin Li, Hao Hu, Hu Y, Xin Chen   +4 more
openalex   +1 more source